Ministers of World Trade Organization (WTO) member countries agreed on a limited waiver of COVID-19 vaccine patents to help developing countries acquire coronavirus vaccines.
Meeting for the first time since 2017, the WTO Ministerial lasted an additional day due to difficulties in achieving a consensus. In certain circumstances, the new decision allows developing countries to make vaccines without having to seek the vaccine patent owner’s approval. Development groups argue that similar vaccine approvals already largely exist, in WTO rules before this deal.
“For countries struggling to protect their people against continued COVID outbreaks, this decision won’t do enough,” said Eric LeCompte, Executive Director of the religious development group Jubilee USA. “After more than two years of a pandemic that cost millions of lives, developing countries need a suspension of multiple WTO rules in order to boost access to vaccines, tests and treatments.”
The International Monetary Fund estimates that more than 100 countries will fail to reach vaccination targets to contain the pandemic globally. WTO members agreed to negotiate possible extensions of the waiver for tests and treatments within six months.
“Tests and treatments should have been part of the same package,” added LeCompte. “Access to tests, treatments and vaccines is essential to limit the threat of new and deadlier mutations that can affect all of us.”
